Login to Your Account

Other news to note

Wednesday, March 19, 2014

Hanmi Pharmaceutical Co. Ltd., of Kyungkido, South Korea, and Access Pharmaceuticals Inc., of New York, entered an exclusive license agreement related to Mugard commercialization in South Korea. Under the terms, Access will receive an up-front licensing fee and double-digit royalties on net sales of Mugard in the licensed territory. Mugard is an oral mucoadhesive that is designed to manage oral mucositis by forming a protective hydrogel coating over the oral mucosa to shield the membranes of the mouth and tongue. Terms were not disclosed.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription